Skip to main content

Genaissance Posts Mild Q2 Revenue Growth, Significant Cut in Net Loss

NEW YORK, Aug. 14 (GenomeWeb News) - Genaissance Pharmaceuticals posted a modest increase in second-quarter revenue amid decreased R&D spending and substantially narrowed net losses.


Total revenue for the period ended June 30 inched up to $3.1 million from $1.9 million one year ago.


R&D spending, meantime, dipped to $5 million from $6.6 million. As a result, net loss in the second quarter receded to $3.8 million, or $.17 per share, from $13.5 million, or $.59 per share, in the second quarter last year.


Genaissance said it had around $23.3 million in cash, cash equivalents, and marketable securities as of June 30.


Click here for more information.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.